Pfizer CEO Sold $5.6 Million Stock in Pre-Planned Sale on Day of Vaccine News Release
We are learning more about a stock sale by Pfizer CEO Albert Bourla on Monday, the same day the company announced its early vaccine trial results. We’ve seen certain circumstances like this before. That’s right… so remember, of course, Pfizer reported that 90 percent efficacy number on its vaccine trial on Monday. Its stock went […]
Pfizer’s Experimental COVID-19 Vaccine 90 Percent Effective?
The German biotech firm BioNTech SE issued a joint press release with its American partner Pfizer, Inc. on Nov. 9, 2020 to announce that interim analysis of a global Phase 3 study of their mRNA-based SARS-CoV-2 vaccine appeared to demonstrate an efficacy rate “above 90%”measured seven days after the second dose.1 “This is really a […]
Pfizer CEO Sells Stock Same Day Positive Results of COVID-19 Vaccine Announced
Story Highlights On Nov. 9, 2020, Pfizer released preliminary Phase 3 clinical trial data indicating that its experimental mRNA COVID-19 vaccine is 90 percent effective, triggering a big surge in stock price. Pfizer CEO Albert Bourla immediately sold 60 percent of his company stock, realizing a gain of $5.6 million in what the company called […]
Another Shot at a Vaccine for Lyme Disease
The U.S. National Institutes of Health (NIH) has provided the University of Maryland with a $3.5 million dollar grant to develop a vaccine for Lyme disease.1 Principal investigators Utal Pal, PhD, professor at the Virginia-Maryland College of Veterinary Medicine at the University of Maryland College of Agriculture and Natural Resources and Matthias Schnell, PhD, director […]
How COVID-19 Vaccine Trials are Designed
There’s been a lot of talk lately about whether or not the fast-tracked COVID-19 vaccine will in fact be safe and effective. While vaccine makers insist that any vaccine reaching the market will have undergone rigorous testing, the way trial protocols are designed suggests these vaccines may leave a lot to be desired. As reported1 by […]
Pharma’s Public Pledge On COVID-19 Vaccines
On Sept. 8, 2020, nine pharmaceutical companies working on COVID-19 vaccines signed a pledge saying they would not submit their experimental vaccines to the U.S. Food and Drug Administration (FDA) unless they were shown to be both safe and efficacious in the Phase 3 human clinical trials.1 2 3 4 5 The pledge, signed by […]